Infective endocarditis due to Enterobacter cloacae resistant to third- and fourth-generation cephalosporins.

Abstract

We report the case of using a long-term combination of meropenem and amikacin to treat infective endocarditis caused by Enterobacter cloacae resistant to third- and fourth-generation cephalosporins. Multi-drug resistant Gram-negative bacilli, such as the E. cloacae in our study, may become possible pathogens of infective endocarditis. Our experience with this case indicates that long-term use of a combination of β-lactam and aminoglycosides might represent a suitable management option for future infective endocarditis cases due to non-Haemophilus, Actinobacillus, Cardiobacterium, Eikenella, Kingella spp. (HACEK group) Gram-negative bacilli such as ours.

• Authors: Yusuke Yoshino, Shu Okugawa, Satoshi Kimura, Eiko Makita, Kazunori Seo, Ichiro Koga, Naohisa Matsunaga, Takatoshi Kitazawa, Yasuo Ota
• Journal: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi (J Microbiol Immunol Infect) Vol. 48 Issue 2 Pg. 226-8 (Apr 2015) ISSN: 1995-9133 [Electronic] England
• PMID: 23017689 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2012. Published by Elsevier B.V.

Chemical References

• Anti-Bacterial Agents
• Cephalosporins
• Thienamycins
• Amikacin
• Meropenem

Topics

• Aged
• Amikacin (therapeutic use)
• Anti-Bacterial Agents (pharmacology, therapeutic use)
• Cephalosporins (pharmacology, therapeutic use)
• Endocarditis (diagnosis, drug therapy, microbiology)
• Enterobacter cloacae (drug effects, isolation & purification)
• Enterobacteriaceae Infections (diagnosis, drug therapy, microbiology)
• Humans
• Male
• Meropenem
• Thienamycins (therapeutic use)
• Treatment Outcome
• beta-Lactam Resistance